The Potential of Tadalafil for Female Sexual Arousal Disorder

Prior studies have demonstrated significant effects of cotreatment with bosentan and

PDE-5 inhibitors on change in 6MWD.3,28,29 To examine these correlations, a backward

Does tadalafil work for low libido in women?

6MWD: 6-minute walk distance; PAH: pulmonary arterial hypertension; VSD: ventricular septal defect; PDA: patent ductus arteriosus; WHO: World Health Organization. For tadalafil-treated patients, males were found to have a significantly greater improvement in 6MWD compared with females (mean [SD]: 48.6 [55] m for males vs. 34.7 [54] m for females; P = 0.01; Table 3). This difference was not statistically significant in the multivariate analysis (P = 0.08) after adjusting for covariates: age, sex, race, etiology of PAH, WHO functional class, background therapy with bosentan, and baseline 6MWD. A backward model selection was performed with 0.05 as the significance level for staying in the model to assess any covariate correlation.

Cite this article

This model selection resulted in elimination of the variables background therapy with bosentan (P = 0.8854), race (P = 0.1935), and sex (P = 0.0647). P = 0.01 for the difference between male and female change in 6MWD. P = 0.49 for the difference between male and sublingual tadalafil female change in TCW. Overall, tadalafil treatment demonstrated a beneficial effect on TCW for patients who experienced clinical worsening compared with placebo in both male and female patients (Table 3). Female patients randomized to receive tadalafil were found to have a shorter mean (SD) TCW compared with male patients randomized to receive tadalafil (61 [29] vs. model selection was performed, which demonstrated that changes in 6MWD are best explained by age, etiology of PAH, WHO functional class, and baseline 6MWD. It can be noted that sex was marginally significant in this patient cohort but that background therapy with bosentan and race were not.

Our study demonstrated a trend toward more progressive worsening in postmenopausal females on the basis of change from baseline 6MWD.

What is tadalafil and how does it work?

In total, 405 subjects (317 females, 88 males) were enrolled in a 16-week, double-blind, double-dummy, placebo-controlled multicenter study. Subjects were randomized into groups receiving placebo or 2.5, 10, 20, or 40 mg of tadalafil once daily. 6MWD was recorded before and after 16 weeks of treatment with tadalafil or placebo in a cohort of 340 subjects (264 females, 76 males).3 Clinical worsening was defined as death, lung or heart-lung transplantation, atrial septostomy, hospitalization due to worsening PAH, initiation of new PAH-approved therapy, or worsening World Health Organization (WHO) functional class over the 16 weeks. 6MWD and WHO functional class were measured at baseline and at weeks 4, 8, 12, and 16. When examining the effect of sex on change in 6MWD and TCW, only the tadalafil-treated patients were included (n = 323; males = 71, females = 252).

Benign prostatic hyperplasia

For the univariate analyses, the Wilcoxon rank sum test was used to assess the effect of sex on change in 6MWD. A log-rank test was used to assess the effect of sex on TCW. Females were subdivided by age as a surrogate for menopausal status: 14–44 years, premenopausal; 45–54 years, perimenopausal; and ≥55 years, postmenopausal (based on the average age of menopause, 52.4 years).25 The linear trend test with first degree of orthogonal polynomials was used to assess the effect of age on change in 6MWD among females and separately for males within the same age groups. A log-rank test was performed on TCW by age among females. Kaplan-Meier plots were constructed to investigate clinical worsening by sex and age. Interestingly, this trend was not seen for males in the same age groups, suggesting that this progressive female worsening is not necessarily due to age.

Who can and cannot take tadalafil?

79 [36] days). A log-rank test did not show a consistent effect of sex on TCW for tadalafil-treated patients (P = 0.49). This difference in TCW between the sexes was found to be not statistically significant in the multivariate analysis (P = 0.41). To assess the impact of menopausal status on treatment response, female subjects were subdivided by age as a surrogate for menopausal status (Table 4). Tadalafil treatment demonstrated a consistent beneficial effect on change in 6MWD from baseline compared with placebo in these subgroups.

Patient resources

For tadalafil-treated patients, there was a trend among female subjects for an age-dependent effect on mean change in 6MWD: the premenopausal group showed the greatest improvement (mean [SD]: 45.7 [55] m), followed by the perimenopausal (mean [SD]: 41.1 [50] m) and the postmenopausal (mean [SD]: 24.5 [54] m) group. The linear trend of the effect of age on 6MWD in females was found to be statistically significant (P = 0.02). This age-related trend was not present in male subjects subdivided into the same age groups: the younger (mean [SD]: 73.2 [48] m) and older (mean [SD]: 42.8 [56] m) men showed greater improvement than middle-aged men (mean [SD]: 34.4 [52] m). Tadalafil was found to have a beneficial effect on TCW for patients who experienced clinical worsening in all female age groups compared with placebo. For tadalafil-treated patients, the log-rank test did not show a consistent age-dependent effect on TCW in females (P = 0.78). Postmenopausal females may likely have more comorbidities than younger women, which may in part account for this trend.

New Competition for Viagra®

In this sex-based post hoc analysis of the PHIRST study that assessed the effect of tadalafil in patients with PAH, we found a significant difference between the sexes in 6MWD change but no consistent effect of sex on TCW. This difference in 6MWD was not significant in the multivariate analysis. In the female population, a trend was tadalafil sale found for greater improvement in 6MWD for premenopausal compared with postmenopausal women. This menopausal status trend was not present for TCW. The baseline characteristics were fairly similar between males and females, with a significant difference in PAH etiology, age, and weight.

Missed Dose

The female cohort reported more atrial septal defects and was slightly younger than the male cohort. Body mass index data were missing for most patients in this study; therefore, it is unclear whether the weight difference between the sexes is physiologically significant. Female patients were grouped according to age as a surrogate marker for menopausal status; significant differences between the age groups in the distribution of PAH etiology and in 6MWD at baseline were noted. It is unclear how significant the etiology distribution was to the overall results, since the majority of each age group consisted of women with idiopathic PAH. The difference in baseline 6MWD did reveal a significantly lower 6MWD for older women, which was considered when evaluating change in 6MWD. This trend may also be related to the low circulating levels of cardioprotective estrogen present after menopause and the

• Tadalafil's duration allows for spontaneous sexual activity.
• It may enhance the physical aspects of female arousal.
• Currently, it's primarily a research medication for women.
• Side effects are similar to those in men, generally mild.
• Use of tadalafil requires medical assessment.
• Its potential role includes improving blood flow during menopause.
• Not recommended for women with contraindicated health issues.
• The drug may support overall sexual wellness.
• Its use should be part of a holistic approach.

estrogen-dependent mechanism of PDE-5 inhibitors.20,30 Ovariectomized mice that were treated with sildenafil did not experience the antiremodeling properties that their

• Tadalafil's impact on female libido is still being explored in research.
• It may help in cases where sexual dysfunction has vascular causes.
• Potential risks include hypotension and priapism, also relevant for women.
• Women with certain health conditions should avoid tadalafil.
• The drug's interaction with other medications warrants caution.
• Women in clinical trials report varied responses.
• Tadalafil might improve erectile tissue engorgement in women.
• It is sometimes used as part of comprehensive sexual therapy.
• Certified healthcare providers should guide its use.

ovary-retaining counterparts did and, interestingly, after exogenous estrogen replacement regained benefit from sildenafil.20 On the basis of these animal data

Our Patient Experience: From Consultation to Results

Our data indicate that males treated with tadalafil may have a clinically significant functional improvement compared with females, supporting the findings of the recently published tadalafil sex-response study.12 The authors of that study suggested that this was due to male patients having lower levels of NO and, therefore, a more robust response to the enhanced NO signaling resulting from PDE-5 inhibition.12,26 Testosterone may also play an important role given its pulmonary vasodilator action via inhibition of the L-type voltage-gated calcium channel.27 It seems likely that the observed difference in functional improvement between the sexes in this study is due to the multifactorial effects of testosterone and estrogen on the pulmonary vasculature. The difference in 6MWD between the sexes for those treated with tadalafil was statistically significant by the nonparametric Wilcoxon rank sum test. After controlling for multiple variables, including age, sex, race, etiology of PAH, WHO functional class, baseline 6MWD, and background therapy with bosentan, the observed differences in 6MWD between the sexes was no longer statistically significant. This may be due to correlation of variables in the multivariate regression model. The correlated variables compete for explaining the change in 6MWD, which may result in variables losing significance compared with the univariate analysis. and the findings of our study, it appears that the treatment mechanism of PDE-5 inhibitors in women may require estrogen.

Additional information

Multivariate linear regression and Cox proportion hazards models were constructed to assess the effect of sex on change in 6MWD and TCW, respectively, by adjusting for age, sex, race, etiology of PAH, WHO functional class, background therapy with bosentan, and baseline 6MWD. Goodness of model fit, colinearity, and numerical stability were also evaluated. Baseline characteristics by sex and menopausal status were collected and are reported in Tables 1 and 2. Between male and female patients, there was a significant difference in baseline weight, PAH etiology, and age. The female cohort was slightly younger (mean age: 53 vs.

Authors and Affiliations

57 years). For female patients, there was a significant difference between menopausal status groups in baseline 6MWD, with postmenopausal females having the lowest baseline 6MWD. In addition, there was a significant difference in PAH pathogenesis across the sex and menopausal states. The majority of each group reported having idiopathic PAH; however, atrial septal defect was predominant in premenopausal females, and cardiovascular disease was predominant in postmenopausal females. Except where otherwise noted, data are no. This raises the question of whether PDE-5 inhibitors should be the optimal therapy for postmenopausal women.

• Tadalafil generally takes about 30-60 minutes to work in women.
• Its effects can last up to 36 hours, providing flexibility.
• It is not a standard treatment but a research tool in women.
• The drug is often compared to sildenafil in studies.
• Women should avoid heavy meals before taking tadalafil.
• Proper hydration may improve its effectiveness.
• Women with hypertension should consult a doctor before use.
• Tadalafil may cause visual disturbances in rare cases.
• Its safety profile in women continues to be studied.

Limitations of this study include inconsistencies in tadalafil dosing and bosentan background therapy.

• Tadalafil's mechanism targets blood vessels to promote dilation.
• It may help women with blood flow-related sexual problems.
• The drug's research status means limited official approvals.
• Female studies explore impacts on sexual satisfaction and arousal.
• Its off-label use is increasing with ongoing research.
• Tadalafil could improve genital flushing and sensitivity.
• Women with cardiac risk factors should avoid tadalafil.
• Clinical trials are testing daily versus as-needed dosing.
• User reports vary, and more evidence is necessary.